Respiratory syncytial virus (RSV) is the most common cause of hospitalization among U.S. infants. CDC recommends RSV vaccination for pregnant persons or administration of RSV antibody (nirsevimab) to infants aged <8 months to prevent RSV lower respiratory tract disease among infants. To determine maternal and infant RSV immunization coverage for the 2023-24 RSV season, CDC conducted an Internet panel survey during March 26-April 11, 2024. Among 678 women at 32-36 weeks' gestation during September 2023-January 2024, 32.6% reported receipt of an RSV vaccine any time during pregnancy. Among 866 women with an infant born during August 2023-March 2024, 44.6% reported receipt of nirsevimab by the infant. Overall, 55.8% of infants were protected by maternal RSV vaccine, nirsevimab, or both. Provider recommendation for maternal vaccination or infant nirsevimab was associated with higher immunization coverage, whereas lack of a provider recommendation was the main reason for not getting RSV immunization. The main reason for definitely or probably not getting nirsevimab for infants was concern about the long-term safety for the infant. Activities supporting providers to make RSV prevention recommendations and have informative conversations with patients might increase the proportion of infants protected against severe RSV disease. CDC and the American College of Obstetricians and Gynecologists have resources to assist providers in effectively communicating the importance of immunization.

中文翻译：

---

<8 个月大的婴儿接种母体呼吸道合胞病毒疫苗和接受呼吸道合胞病毒抗体 （Nirsevimab） - 美国，2024 年 4 月。


呼吸道合胞病毒 （RSV） 是美国婴儿最常见的住院原因。CDC 建议孕妇接种 RSV 疫苗或对 <8 个月大的婴儿接种 RSV 抗体 （nirsevimab），以预防婴儿患 RSV 下呼吸道疾病。为了确定 2023-24 年 RSV 季节的孕产妇和婴儿 RSV 免疫覆盖率，CDC 在 2024 年 3 月 26 日至 4 月 11 日期间进行了一项互联网小组调查。在 2023 年 9 月至 2024 年 1 月期间，在 678 名妊娠 32-36 周的妇女中，32.6% 的人报告在怀孕期间的任何时间都接种了 RSV 疫苗。在 2023 年 8 月至 2024 年 3 月期间出生的 866 名有婴儿的妇女中，44.6% 的人报告婴儿接受了 nirsevimab。总体而言，55.8% 的婴儿受到母体 RSV 疫苗、nirsevimab 或两者的保护。提供者推荐母体疫苗接种或婴儿 nirsevimab 与更高的免疫覆盖率相关，而缺乏提供者推荐是未接受 RSV 免疫接种的主要原因。婴儿肯定或可能不会接受 nirsevimab 的主要原因是担心婴儿的长期安全。支持提供者提出 RSV 预防建议并与患者进行信息对话的活动可能会增加免受严重 RSV 疾病保护的婴儿的比例。CDC 和美国妇产科医师学会 （American College of Obstetricians and Gynecologists） 拥有资源，可协助提供者有效宣传免疫接种的重要性。